IP Library Granted Patent US 9,150,928
Granted Patent B2
US 9,150,928 · App. 13/885,762 · Granted Oct 6, 2015

Diagnosing and monitoring CNS malignancies using MicroRNA

Inventors: Anna M. Krichevsky (Brookline, MA); Nadiya Teplyuk (Boston, MA); Brit Mollenhauer (Kassel, DE); Santosh Kesari (San Diego, CA)
Assignees: The Brigham and Women's Hospital, Inc.; The Regents of the University of California
C12Q1/6886G06F19/18C12Q2600/118C12Q2600/178G06F19/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,150,928
App. No.
13/885,762
Granted
Oct 6, 2015
Kind
B2
Abstract

The use of specific microRNAs (miRNAs) present in CSF as biomarkers for particular brain malignancies and disease activity.

Claims (26)

1. A method of detecting or making a diagnosis between metastatic and primary brain tumors, the method comprising:

determining, using real time polymerase chain reaction (RT-PCR) or an RNA expression assay, levels of miR-10b, miR-21, and miR-200 in a sample comprising cerebrospinal fluid (CSF) from a subject, and

comparing the levels of miR-10b, miR-21, and miR-200 to reference levels of miR-10b, miR-21, and at least one miR-200 family member, and

determining that the subject does not have a metastatic or primary brain tumor when the levels of all of miR200, miR-10b or miR-21 are below the reference levels;

diagnosing a metastatic or primary brain tumor in a subject who has levels of miR-10b or miR-21 above the reference levels, and administering a treatment for a metastatic or primary brain tumor to the subject; and

diagnosing a metastatic brain tumor when the levels of the miR-200 family member are above the reference level, and administering a treatment for metastatic brain cancer to a subject who has levels of the miR-200 family member above the reference level.

2. The method of claim 1 , wherein the miR-200 family member is selected from the group consisting of miR-200a, miR-200b, and miR-200c.

3. A computer-implemented method of assigning a sample into a category, the method comprising:

determining levels of miR-10b, miR-21, and at least one miR-200 family member, in a sample comprising cerebrospinal fluid (CSF) from a subject, to provide a subject dataset;

downloading the subject dataset into a computer system having a memory, an output device, and a processor programmed for executing an algorithm, wherein the algorithm assigns the datasets into one of two categories using levels of miR-10b, miR-21, and at least one miR-200 family member;

assigning the subject dataset into the first or second category using the programmed processor; and

generating an output comprising a report indicating the assignment to the first or second category.

4. The method of claim 3 , wherein the first category is presence of a primary brain tumor and the second category is presence of a metastatic brain tumor.

5. The method of claim 3 , wherein the first category is presence of a primary brain tumor or a metastatic brain tumor, and the second category is absence of a primary brain tumor or a metastatic brain tumor.

6. The method of claim 3 , wherein the algorithm is a linear algorithm or radial basis function.

7. The method of claim 3 , wherein the algorithm is a linear algorithm comprising: (a*miR-125b)+(b*miR-10b)+(c*miR-21)+(d*miR-141)+(e*miR-200a)+(f*miR-200b)+(g*miR-200c)−h, wherein a-g are weights and h is a constant.

8. The method of claim 3 , wherein the miR-200 family member is selected from the group consisting of miR-200a, miR-200b, miR-200c, miR-141, and miR-429.

9. A method of detecting or making a diagnosis between metastatic and primary brain tumors, the method comprising:

determining, using real time polymerase chain reaction (RT-PCR) or an RNA expression assay, levels of miR-10b, miR-21, and at least one miR-200 family member in a sample comprising cerebrospinal fluid (CSF) from a subject, and

using a suitably programmed processor to apply a linear algorithm to the levels of miR-10b, miR-21, and miR-200 to classify the sample as (i) a primary brain tumor or (ii) a metastatic brain tumor, and

diagnosing a metastatic brain tumor in a subject classified as having a metastatic brain tumor, and diagnosing a primary brain tumor in a subject classified as having a primary brain tumor.

10. The method of claim 9 , comprising:

selecting a subject classified as having a metastatic brain tumor, and administering a treatment for metastatic brain cancer to the subject; or

selecting a subject classified as having a metastatic or primary brain tumor, and

administering a treatment for primary brain cancer to the subject.

11. The method of claim 9 , comprising determining levels of miR-125b, miR-10b, miR-21, miR-141, miR-200a, miR-200b, and miR-200c, wherein the linear algorithm comprises: (a*miR-125b)+(b*miR-10b)+(c*miR-21)+(d*miR-141)+(e*miR-200a)+(f*miR-200b)+(g*miR-200c)−h, wherein a-g are weights and h is a constant.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 31, 2015
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036515/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2013
From: KRICHEVSKY, ANNA M.; TEPLYUK, NADIYA; MOLLENHAUER, BRIT
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 031116/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2013
From: KESARI, SANTOSH
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 031116/0170 →
Continuity (2)
Provisional Application 61457000 · Nov 16, 2010
Related Publication 20130344063A1 · Dec 26, 2013